A new generation of non-invasive tests of liver fibrosis with improved accuracy in MASLD.

Background & Aims: The accuracy of non-invasive tests (NITs) should be ≥80% (EASL recommendation). We aimed to compare the accuracies of the recommended NITs for advanced fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) and improve NIT accuracy.

Methods: A total of 1,051 patients with MASLD were allocated to derivation (n = 637) and validation (n = 414) sets.

Prognostic impact of circulating tumor DNA detection in portal and peripheral blood in resected pancreatic ductal adenocarcinoma patients.

In PDAC patients, ctDNA detection's prognostic significance needs validation especially in resected patients. This study investigated ctDNA kinetics in portal and peripheral blood before and after resection, and whether tissue mobilization during surgery influences ctDNA detection. In this single-center prospective cohort, portal and peripheral blood were drawn during pancreaticoduodenectomy before and after tissue mobilization, during 12 postoperative months and were associated with overall survival (OS), recurrence-free survival (RFS) and CA19-9 (secondary endpoints).

A Qualitative Analysis of Sexual Fantasies Among Childhood Sexual Abuse Survivors and Non-Victims.

Research suggests childhood sexual abuse (CSA) has an impact on survivor's sexual fantasies; however, empirical research is inconclusive. As sexual fantasies play a crucial role in sexual well-being, more exploration of sexual fantasies in CSA survivors and non-victims is needed. An online survey-based content analysis was conducted on fantasies reported by CSA survivors ( = 48) and non-victims ( = 44).

MASLD-related HCC: Multicenter study comparing patients with and without cirrhosis.

Background & Aims: Despite its growing incidence, hepatocellular carcinoma (HCC) related to metabolic dysfunction-associated steatotic liver disease (MASLD) in non-cirrhotic livers remains poorly characterized. We compared the characteristics, management, survival, and trends of MASLD-related HCC in patients with or without underlying cirrhosis in a large multicenter cohort.

Methods: A total of 354 cases of MASLD-related HCC presented at the liver tumor meetings of four French university hospitals between 2007 and 2018 were included in the study.